The Journal of Urology
Volume 179, Issue 2 , Pages 485-490, February 2008

Prevention of Recurrence With Epirubicin and Lactobacillus Casei After Transurethral Resection of Bladder Cancer

  • Seiji Naito

      Affiliations

    • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    • Corresponding Author InformationCorrespondence: Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan (telephone: +81-92-642-5601; FAX: +81-92-642-5618).
  • ,
  • Hirofumi Koga

      Affiliations

    • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • ,
  • Akito Yamaguchi

      Affiliations

    • Department of Urology, Harasanshin General Hospital, Fukuoka, Japan
  • ,
  • Naohiro Fujimoto

      Affiliations

    • Department of Urology, University of Occupational and Environmental Health, Miyazaki, Japan
  • ,
  • Yoshihiro Hasui

      Affiliations

    • Department of Urology, Kitakyushu and Miyazaki Medical College, Miyazaki, Japan
  • ,
  • Hiroshi Kuramoto

      Affiliations

    • Department of Urology, Moji Rousai Hospital, Miyazaki, Japan
  • ,
  • Atsushi Iguchi

      Affiliations

    • Department of Urology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
  • ,
  • Naoko Kinukawa

      Affiliations

    • Department of Medical Information on Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • ,
  • Kyushu University Urological Oncology Group

Received 2 May 2007 published online 12 December 2007.

Purpose

A prospective, randomized, controlled trial was done to evaluate whether oral administration of a preparation of the probiotic agent Lactobacillus casei (Yakult Honsha, Tokyo, Japan) could enhance the prevention of recurrence by intravesical instillation of epirubicin after transurethral resection for superficial bladder cancer.

Materials and Methods

Between August 1999 and December 2002, 207 patients clinically diagnosed with superficial bladder cancer were included as study candidates and underwent transurethral resection, followed by intravesical instillation of 30 mg epirubicin/30 ml saline twice during 1 week. After histological confirmation of superficial bladder cancer they were again included as study participants with 102 randomized to receive treatment with 6 additional intravesical instillations of epirubicin during the 3-month period after transurethral resection (epirubicin group) and 100 randomized to intravesical chemotherapy on the same schedule as the epirubicin group plus oral administration of 3 gm Lactobacillus casei preparation per day for 1 year (epirubicin plus Lactobacillus casei group). Patients were evaluated for intravesical recurrence, disease progression, prognosis and adverse drug reactions.

Results

The 3-year recurrence-free survival rate was significantly higher in the epirubicin plus Lactobacillus casei group than in the epirubicin group (74.6% vs 59.9%, p = 0.0234), although neither progression-free nor overall survival differed between the groups. The incidence of adverse drug reactions did not significantly differ between the groups and there were no serious adverse drug reactions.

Conclusions

Intravesical instillation of epirubicin plus oral administration of Lactobacillus casei preparation is a novel, promising treatment for preventing recurrence after transurethral resection for superficial bladder cancer.

Key Words: bladder, bladder neoplasms, neoplasm recurrence, local, epirubicin, Lactobacillus casei

Abbreviations and Acronyms: BCG, bacillus Calmette-Guerin, EPI-ADM, epirubicin, LC, Lactobacillus casei, TUR, transurethral resection

 

 Study received local institutional review board approval.

 For another article on a related topic see page 743.

PII: S0022-5347(07)02531-1

doi:10.1016/j.juro.2007.09.031

Refers to article:

  • Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer , 14 December 2007

    Mohammad Obaidul Hoque, Shahnaz Begum, Mariana Brait, Carmen Jeronimo, Marianna Zahurak, Kimberly Laskie Ostrow, Eli Rosenbaum, Bruce Trock, William H. Westra, Mark Schoenberg, Steven N. Goodman, David Sidransky
    The Journal of Urology February 2008 (Vol. 179, Issue 2, Pages 743-747)

The Journal of Urology
Volume 179, Issue 2 , Pages 485-490, February 2008